Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.

Pharmacogenomics - 1 Sept 2014

Silvestris Nicola, Vincenzi Bruno, Brunetti Anna Elisabetta, Loupakis Fotious, Dell'Aquila Emanuela, Russo Antonio, Scartozzi Mario, Giampieri Riccardo, Cascinu Stefano, Lorusso Vito, Tonini Giuseppe, Falcone Alfredo, Santini Daniele

Abstract excerpt

Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to ras Proteins

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 25410895
DOI: 10.2217/pgs.14.124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.PMID 25410895Read ↗

Impact of cetuximab in current treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?Semantic proximity Read ↗

Cetuximab in the treatment of patients with colorectal cancer.Semantic proximity Read ↗

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.Semantic proximity Read ↗

KRAS status predicts response to cetuximab for metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.Semantic proximity Read ↗

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer TreatmentSemantic proximity Read ↗

[Biomarkers of Anti-EGFR Antibodies in the Treatment of Metastatic Colorectal Cancer].Semantic proximity Read ↗

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.Semantic proximity Read ↗

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.Semantic proximity Read ↗

Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.